Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Saxman, K. Propert, L. Einhorn, E. Crawford, I. Tannock, D. Raghavan, P. Loehrer, D. Trump (1997)
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 7
H. Herr, D. Bajorin, H. Scher (1998)
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 4
D. Skinner, J. Daniels, C. Russell, G. Lieskovsky, STUART Boyd, P. Nichols, W. Kern, Joanne Sakamoto, M. Krailo, S. Groshen (1991)
The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial.The Journal of urology, 145 3
M. Stöckle, W. Meyenburg, S. Wellek, G. Voges, U. Gertenbach, J. Thüroff, C. Huber, R. Hohenfellner (1992)
Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study.The Journal of urology, 148 2 Pt 1
C.J. Logothetis, F.H. Dries, A. Sell (1990)
A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumorsJ Clin Oncol, 8
D. Bajorin, P. Dodd, Madhu Mazumdar, M. Fazzari, J. McCaffrey, H. Scher, H. Herr, G. Higgins, M. Boyle (1999)
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 10
P.S. Hemanek (1987)
UICC-International Union Against Cancer: TNM classification of malignant tumors
C. Logothetis, F. Dexeus, L. Finn, A. Sella, R. Amato, A. Ayala, R. Kilbourn (1990)
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 6
E. Winquist, T. Kirchner, R. Segal, J. Chin, H. Lukka (2004)
Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.The Journal of urology, 171 2 Pt 1
H. Maase, S. Hansen, J. Roberts, L. Dogliotti, T. Oliver, M. Moore, I. Bodrogi, P. Albers, A. Knuth, C. Lippert, P. Kerbrat, P. Rovira, P. Wersåll, S. Cleall, D. Roychowdhury, I. Tomlin, C. Visseren-Grul, P. Conte (2000)
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 17
J. Stein, G. Lieskovsky, R. Cote, S. Groshen, An‐Chen Feng, STUART Boyd, E. Skinner, B. Bochner, D. Thangathurai, M. Mikhail, D. Raghavan, D. Skinner (2001)
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 3
H. Frazier, J. Robertson, R. Dodge, D. Paulson (1993)
The value of pathologic factors in predicting cancer‐specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostateCancer, 71
T. Splinter, H. Scher, L. Denis, R. Bukowski, Sergio Simon, I. Klimberg, M. Soloway, N. Vogelzang, H. Tinteren, H. Herr (1992)
The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.The Journal of urology, 147 3
A.B. Sarkis, D.F. Bajorin, V.E. Reuter (1995)
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVACJ Clin Oncol, 13
C. Sternberg, P. Mulder, J. Schornagel, C. Théodore, S. Fosså, A. Oosterom, F. Witjes, M. Spina, C. Groeningen, C. Balincourt, L. Collette (2001)
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of CancerJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 10
E. Winquist, T.S. Kirchner, R. Segal (2004)
Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysisJ Urol, 171
H.W. Herr, H.I. Scher (1994)
Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancerJ Clin Oncol, 12
P. Loehrer, L. Einhorn, P. Elson, E. Crawford, P. Kuebler, I. Tannock, D. Raghavan, R. Stuart-Harris, M. Sarosdy, B. Lowe (1992)
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 7
H. Scher, H. Herr, C. Sternberg, W. Fair, G. Bosl, M. Morse, P. Sogani, R. Watson, D. Dershaw, V. Reuter (1989)
Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen.British journal of urology, 64 3
M. Dimopoulos, L. Moulopoulos (1998)
Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 4
B. Fisher, J. Bryant, N. Wolmark, E. Mamounas, Anna Brown, E. Fisher, D. Wickerham, M. Begovic, A. DeCillis, A. Robidoux, R. Margolese, A. Cruz, J. Hoehn, A. Lees, N. Dimitrov, H. Bear (1998)
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 8
Alvoro Sarkis, D. Bajorin, V. Reuter, H. Herr, G. Netto, Zuo‐Feng Zhang, P. Schultz, C. Cordon-Cardo, H. Scher (1995)
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.The Journal of urology, 154 5
C.N. Sternberg, V. Pansadoro (2000)
Comprehensive textbook of genitourinary oncology
C. Sternberg, A. Yagoda, H. Scher, R. Watson, N. Geller, H. Herr, M. Morse, P. Sogani, E. Vaughan, N. Bander, L. Weiselberg, K. Rosado, T. Smart, Shiow‐Yun Lin, D. Penenberg, W. Fair, W. Whitmore (1989)
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseCancer, 64
M. Stockle, W. Meyenburg, S. Wellek (1992)
Advanced bladder cancer: improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy: results of a controlled prospective studyJ Urol, 148
A. Jemal, Taylor Murray, Elizabeth Ward, A. Samuels, R. Tiwari, Asma Ghafoor, E. Feuer, M. Thun (2005)
Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 55
H. Herr, H. Scher (1994)
Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer.Cancer treatment and research, 59
J. Gabrilove, A. Jakubowski, H. Scher, C. Sternberg, G. Wong, J. Grous, A. Yagoda, Katherine Fain, M. Moore, B. Clarkson, H. Oettgen, K. Alton, K. Welte, L. Souza (1988)
Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the UrotheliumThe New England Journal of Medicine, 318
(1997)
AJCC cancer staging manual
R. Millikan, C. Dinney, D. Swanson, Paul Sweeney, Jae Ro, Terry Smith, Dallas Williams, C. Logothetis (2001)
Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 20
R. Sánchez-Ortiz, W. Huang, R. Mick, K. Arsdalen, A. Wein, S. Malkowicz (2003)
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma.The Journal of urology, 169 1
T.A. Splinter, H.I. Scher, L. Denis (1992)
The prognostic value of pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancerJ Urol, 147
J. Holland, E. Frei, D. Kufe, R. Bast (2003)
Adjuvant and Neoadjuvant Chemotherapy
Despite radical cystectomy for muscle-invasive bladder cancer, approximately 50% of patients with this disease will develop metastatic progression. Neoadjuvant systemic chemotherapy can be administered to decrease the risk of recurrence. Multiple randomized trials have addressed the effect of neoadjuvant chemotherapy on survival in patients with muscle-invasive bladder cancer. A recently published meta-analysis demonstrated a survival benefit with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.